If you followed this class of medicines in 2023 and 2024, you will remember the shortages that were widely reported across Europe at the time: starter doses that were hard to find, pharmacies ringing round for stock, treatment interrupted mid-titration. That period shaped expectations that are now out of date.

The overview below is generated from the Czech drug regulator's own supply register and refreshes automatically, so it reflects the current national position rather than the day this article was written.

Each pill is one strength, colour-coded by its supply status. Read it as the national picture: what is being supplied in Czechia, not what any individual pharmacy has on the shelf today.

The national picture in 2026

The headline: the broad shortages are over. Across the main GLP-1 products supplied in Czechia, the principal strengths are recorded as being on the market, including the low starter strengths that were hardest to find two years ago. If you are starting treatment now, you are not stepping into the situation people faced in 2023.

Two entries in the register look alarming and are not.

The first is discontinued pack variants. A single strength can exist in more than one pack format, and manufacturers retire old formats while the replacement keeps shipping. A strength marked discontinued alongside the same strength on the market is usually a pack format being phased out, not the dose disappearing.

The second is the oral tablet product. Several original tablet strengths are recorded as discontinued while a different set is on the market. That is a change to the range offered, not a national shortage, and a detail worth raising with your doctor rather than inferring from a database.

How Czech supply reporting works

Marketing authorisation holders are legally required to notify SÚKL, the State Institute for Drug Control, when they start supplying a medicine, interrupt supplies, resume them or stop altogether (SÚKL). Those notifications feed a register that is published as open data and updated daily (SÚKL open data catalogue), which is exactly what the overview above reads from.

When SÚKL judges that supply does not meet patient needs and no therapeutic alternative exists, it can designate a medicine as having limited availability. That caps how much pharmacies may order, near their usual weekly dispensing over the preceding twelve months, which stops stockpiling and spreads scarce supply more evenly. It also makes stock information publicly visible.

"On the market" is not the same as "in stock at your pharmacy"

This is the distinction that causes the most frustration. The register records whether a product is being supplied to the Czech market nationally. It does not record what is on the shelf of the pharmacy nearest your flat. A medicine can be available nationally and still be absent from a specific pharmacy on a specific afternoon, particularly for less commonly dispensed strengths and in smaller towns.

So treat the national picture as the answer to "is this supplied in Czechia at all", and treat a phone call to your pharmacy as the answer to "can I collect it today". Only the pharmacy can answer the second one.

Your prescription is not tied to one pharmacy

A Czech electronic prescription is not bound to the pharmacy, city or region where it was issued. It can be dispensed at any pharmacy in the country, so if the first cannot supply you today, try another or ask them to order it in. Pharmacies can often check stock at other branches in their chain and order stock from their supplier.

One detail matters specifically for foreign residents. Czech pharmacies can normally pull up your prescription from your ID, but that lookup depends on being matchable in Czech identity records, so bring your prescription code rather than relying on it. With the code, received by SMS or as a printout, any pharmacy can dispense against it without finding you in a system. Our guide to the eRecept explains this in more detail.

The same portability is why a prescription issued in Czechia is more dependable here than one brought from abroad. Cross-border recognition of foreign electronic prescriptions works only at participating pharmacies, and the list is limited (epreskripce.gov.cz). If you have moved here and are continuing treatment started elsewhere, this article covers the transition.

If the strength you need is not available

Work through this in order, because the order matters.

Do not adjust the treatment yourself. Do not switch strengths, split or stretch doses, or substitute a different product because it is the one in stock. Any change to the regimen is a decision for the doctor supervising your treatment.
Ask the pharmacist. They can check supplier stock, order for you, and often tell you which nearby pharmacy has it. This is usually the fastest route.
Try another pharmacy. Your prescription works anywhere in the country, so use that.
Check the register. Reported interruptions and expected resumption dates are published by SÚKL.
Tell your doctor if it is not a one-off. If something is genuinely unavailable for a sustained period, your doctor decides what happens next, including whether an alternative is appropriate.

Why supply gaps attract counterfeiters

Every supply gap creates a market for people willing to exploit it. SÚKL has issued alerts about falsified versions of these medicines: suspected counterfeit Ozempic identified elsewhere in the EU, and a counterfeit Mounjaro KwikPen batch detected in Brazil. In both cases SÚKL states the falsified product was not found in the Czech legal distribution chain, which is precisely the protection you lose the moment you buy outside a pharmacy.

The rules that protect you are simple. Every medicine in this class is prescription-only, so an offer that skips the prescription is illegal by definition. Prescription medicines cannot legally be posted to you in Czechia, because mail-order dispensing is limited to medicines that do not require a prescription (SÚKL), so home delivery offers are a warning sign. Social media sellers and classified ads are not a supply chain. Our article on illegal online pharmacies covers how to recognise them.

Availability is the last question, not the first

It is easy to spend a long time researching stock levels for a treatment you may never be prescribed. Whether treatment is appropriate is a clinical decision made by a doctor who reviews your health history, your current medications and your goals, and who may conclude that treatment is not suitable and decline to prescribe. Sometimes an in-person examination is needed first. These medicines carry real contraindications and side effects: most commonly gastrointestinal ones such as nausea, vomiting and constipation, and rarely serious complications that need immediate medical attention. They are not for use in pregnancy or while breastfeeding, and some personal or family medical histories rule them out entirely. The full risk profile sits in the approved product information published by the European Medicines Agency.

If you want to compare what is actually licensed and used here, with the limitations of each, see our comparison of GLP-1 medicines in Czechia. Costs are covered separately in what treatment costs in CZK.

Frequently asked questions

Is Wegovy available in the Czech Republic right now?

According to the SÚKL supply register its main strengths are recorded as being on the market, and the overview at the top of this page reflects the live position. National availability does not guarantee your local pharmacy has stock today, so call ahead before travelling.

Does national availability mean my Prague pharmacy has it?

No. The register records what is supplied to the Czech market as a whole, while stock at individual pharmacies varies day to day, and less commonly dispensed strengths can be harder to find. A Czech prescription can be filled at any pharmacy in the country, so if one branch cannot supply you, another or an order usually will.

What should I do if my pharmacy does not have my dose?

Ask the pharmacist to check availability or order it, and try another pharmacy, since a Czech prescription is valid nationwide. Do not switch strengths or products on your own initiative. If the problem persists, contact the doctor supervising your treatment.

Are the 2023 and 2024 shortages over?

Broadly yes. The main strengths are recorded as being on the market in the national supply register, a considerably better position than the peak shortage period. Individual pack formats are still occasionally retired or interrupted, so check the live overview rather than assuming.